`

Acumen Pharmaceuticals, Inc

Biotechnology Research

Specialities :
Alzheimer's disease
Neurodegenerative disease
Therapeutics
Amyloid-beta oligomers
Monoclonal anitbodies

+1

revenue-icon Revenue
11M - 100M
funding-icon Total Funding
$50.0M
size-icon Size
51 - 200

Frequently Asked Questions About Acumen Pharmaceuticals, Inc

What does Acumen pharmaceuticals, inc do?+

Acumen is forging a new path towards safe and effective treatments for Alzheimers disease and other neurodegenerative diseases through our focus on the biology of toxic soluble amyloid-beta oligomers. Our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (Ao) in synaptic dysfunction and neurodegeneration. These early insights have fostered decades of research on the biology of Ao at Acumen and throughout the field. We are now on the on cusp of realizing the therapeutic potential of Ao targeted drugs

What are Acumen pharmaceuticals, inc's specialties? +

Alzheimer's disease,neurodegenerative disease,therapeutics,amyloid-beta oligomers,monoclonal anitbodies,and immunotherapy

What is Acumen pharmaceuticals, inc's industry? +

Acumen pharmaceuticals, inc operates in the Biotechnology research industry.

What is Acumen pharmaceuticals, inc's revenue? +

Acumen pharmaceuticals, inc's revenue is 11m - 100m

What is Acumen pharmaceuticals, inc's company size? +

Acumen pharmaceuticals, inc has 51 - 200 employees.

The Go-to Sales Technology According to G2

G2 Badges Map
Get Started With Clodura
Sign Up

Sign Up for Free

Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.

Supercharge Your Prospecting

Supercharge Your Prospecting

Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.

Grow Your Business

Grow Your Business

Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.